harpoon
therapeutics
appoints
omer
siddiqui
vp
development
operations
project
management
south
san
francisco
globe
newswire
harpoon
therapeutics
nasdaq
harp
immunotherapy
company
developing
novel
class
cell
engagers
today
announced
appointment
omer
siddiqui
vice
president
development
operations
project
management
siddiqui
joins
harpoon
recently
alector
served
vice
president
head
development
operations
delighted
omer
joining
harpoon
lead
development
operations
support
expanding
clinical
portfolio
said
jerry
mcmahon
president
chief
executive
officer
harpoon
therapeutics
extensive
background
experience
oncology
drug
clinical
development
business
operations
portfolio
strategy
project
management
asset
continue
advance
product
candidate
pipeline
cell
engagers
treatment
solid
tumor
hematologic
omer
siddiqui
r
leader
oncology
expertise
early
clinical
development
multiple
therapeutic
areas
head
development
operations
alector
led
clinical
development
planning
strategy
progress
three
antibody
programs
research
clinic
resulted
substantial
pharma
partnership
also
built
clinical
groups
oversee
ongoing
future
clinical
programs
previous
career
experience
includes
clinical
operations
management
allakos
genentech
inc
research
siddiqui
received
msc
biotechnology
johns
hopkins
university
bsc
biology
university
western
ontario
harpoon
therapeutics
harpoon
therapeutics
immunotherapy
company
developing
novel
class
cell
engagers
harness
power
body
immune
system
treat
patients
suffering
cancer
diseases
cell
engagers
engineered
proteins
direct
patient
cells
kill
target
cells
express
specific
proteins
antigens
carried
target
cells
using
proprietary
cell
activating
construct
platform
harpoon
developing
pipeline
novel
tritacs
initially
focused
treatment
solid
tumors
hematologic
malignancies
targets
psma
phase
trial
metastatic
prostate
cancer
targets
mesothelin
phase
trial
cancers
expressing
mesothelin
including
ovarian
pancreatic
cancers
targets
bcma
phase
trial
relapsed
refractory
multiple
myeloma
targets
harpoon
plans
initiate
trial
second
half
additional
information
harpoon
therapeutics
please
visit
cautionary
note
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
words
may
expect
plan
anticipate
target
estimate
intend
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
based
harpoon
therapeutics
expectations
assumptions
date
press
release
statements
involves
risks
uncertainties
could
cause
harpoon
therapeutics
clinical
development
programs
future
results
performance
differ
significantly
expressed
implied
statements
statements
contained
press
release
include
limited
statements
progress
timing
scope
anticipated
results
clinical
trials
timing
presentation
data
association
data
potential
treatment
outcomes
development
advancement
product
candidates
timing
development
milestones
product
candidates
anticipated
potential
impacts
harpoon
therapeutics
business
ongoing
pandemic
many
factors
may
cause
differences
current
expectations
actual
results
including
unexpected
safety
efficacy
data
observed
clinical
studies
clinical
trial
site
activation
enrollment
rates
lower
expected
unanticipated
greater
anticipated
impacts
delays
due
changes
expected
existing
competition
changes
regulatory
environment
uncertainties
timing
regulatory
approval
process
unexpected
litigation
disputes
factors
may
cause
harpoon
therapeutics
actual
results
differ
expressed
implied
statements
press
release
discussed
harpoon
therapeutics
filings
securities
exchange
commission
including
risk
factors
sections
contained
therein
except
required
law
harpoon
therapeutics
assumes
obligation
update
statements
contained
herein
reflect
change
expectations
even
new
information
becomes
available
contacts
harpoon
therapeutics
georgia
erbez
chief
financial
officer
media
westwicke
icr
robert
uhl
managing
director
